Background-Obesity and the metabolic syndrome frequently coexist. Both are associated with cardiovascular disease (CVD). However, the contribution of obesity to cardiovascular risk, independent of the presence of the metabolic syndrome, remains controversial. Methods and Results-From the WISE study, 780 women referred for coronary angiography to evaluate suspected myocardial ischemia were classified by body mass index (BMI; Ͻ24.9ϭnormal, nϭ184; Ն25.0 to Յ29.9ϭoverweight, nϭ269; Ն30.0ϭobese, nϭ327) and presence (nϭ451) or absence (nϭ329) of the metabolic syndrome, further classified by diabetes status. Prevalence of significant angiographic coronary artery disease (CAD; Ն50% stenosis) and 3-year risk of CVD were compared by BMI and metabolic status. The metabolic syndrome and BMI were strongly associated, but only metabolic syndrome was associated with significant CAD. Similarly, unit increases in BMI (normal to overweight to obese) were not associated with 3-year risk of death (adjusted hazard ratio [HR] 0.92, 95% CI 0.59 to 1.51) or major adverse cardiovascular event (MACE: death, nonfatal myocardial infarction, stroke, congestive heart failure; adjusted HR 0.95, 95% CI 0.71 to 1.27), whereas metabolic status (normal to metabolic syndrome to diabetes) conferred an approximate 2-fold adjusted risk of death (HR 2.01, 95% CI 1.26 to 3.20) and MACE (HR 1.88, 95% CI 1.38 to 2.57). Levels of C-reactive protein (hs-CRP) were more strongly associated with metabolic syndrome than BMI but were not independently associated with 3-year risk of death or MACE. Conclusions-The metabolic syndrome but not BMI predicts future cardiovascular risk in women. Although it remains prudent to recommend weight loss in overweight and obese women, control of all modifiable risk factors in both normal and overweight persons to prevent transition to the metabolic syndrome should be considered the ultimate goal. 
I
n the United States, more than 60% of adult women are overweight. During the past 3 decades, the prevalence of obesity has doubled from approximately 15% to 30%. 1, 2 Obesity is associated with conventional cardiovascular risk factors (eg, hypertension, dyslipidemia, and diabetes mellitus), 3, 4 novel risk factors (eg, inflammatory markers such as high-sensitivity C-reactive protein [hs-CRP] and interleukin-6 [IL-6]), 5 and coronary artery endothelial dysfunction. 6 These associations provide a plausible biological link to epidemiological observations that indicate that obesity is associated with increased risks of both nonfatal and fatal cardiovascular events in women. [7] [8] [9] [10] However, there is substantial heterogeneity of metabolic abnormalities in obese patients, and there remains controversy as to the role of obesity as an independent etiologic factor for incident cardiovascular disease. 5 Abdominal adiposity is 1 of 5 clinical criteria (including hypertriglyceridemia, low HDL cholesterol, hypertension, and fasting hyperglycemia) that when Ն3 are present define the metabolic syndrome as set forth by the National Cholesterol Education Program (NCEP) Adult Treatment Panel (ATP) III. 11 The prevalence of the metabolic syndrome currently exceeds 20% of individuals Ն20 years of age and 40% of the population Ͼ40 years of age. 12 Like obesity, the presence of the metabolic syndrome has been associated with risks of developing diabetes 13 and cardiovascular dis-ease. 14 -17 Insulin resistance is believed to play a central pathophysiological role in the metabolic syndrome. 18 However, obesity and the metabolic syndrome/insulin resistance do not uniformly coexist; a significant proportion of persons defined as obese do not develop insulin resistance, and, conversely, insulin resistance can be present in lean individuals. 16 Chronic subclinical inflammation, which is associated with cardiovascular risk, is believed to be part of the metabolic syndrome. 19 Epidemiological studies indicate that the predictive power of the metabolic syndrome for cardiovascular disease may be enhanced by the presence of inflammation manifested by high levels of hs-CRP. 20 Despite these observations, measures of hs-CRP are not currently included in the definition of the metabolic syndrome. 21 This is particularly relevant to the cardiovascular risk stratification of women, in whom high levels of hs-CRP are associated with development of the metabolic syndrome independent of levels of adiposity. 22 In the present study of a cohort of women with suspected myocardial ischemia, we evaluated the relative influence of body weight per se versus the metabolic syndrome on the prevalence of significant angiographic coronary artery disease (CAD), as well as incident cardiovascular disease. Furthermore, we explored the potential role of inflammation in the predictive value of body weight and metabolic status.
Methods

Study Population
The study population consisted of 780 (83%) of 944 women enrolled in the Women's Ischemia Syndrome Evaluation (WISE) study, aged 21 to 86 years, in whom the presence or absence of the metabolic syndrome (defined below) could be determined. By study protocol, all women were clinically referred for coronary angiography to evaluate suspected myocardial ischemia at 1 of 4 sites (University of Alabama at Birmingham; University of Florida, Gainesville; University of Pittsburgh, Pittsburgh, Pa; and Allegheny General Hospital, Pittsburgh, Pa). 23 Exclusion criteria included pregnancy, cardiomyopathy, New York Heart Association class IV angina, congestive heart failure, recent myocardial infarction or revascularization, and any contraindications to provocative testing. All subjects provided informed consent and completed research forms approved by the institutional review board at their local WISE clinical site. On enrollment in the study, each woman had a baseline evaluation that included collection of demographic information, risk factors for CAD, medication use, medical and reproductive history, symptom and psychosocial evaluation, a physical examination with blood pressure and physical measurements, and sampling of blood in the fasting state for lipid, glucose, insulin, reproductive hormone, and inflammatory marker core laboratory evaluations.
Classification of Metabolic Status
The ATP III criteria 11 were used to classify study participants as being with or without the metabolic syndrome based on the presence or absence of Ն3 of the following factors: (1) waist circumference Ͼ88 cm, (2) fasting triglycerides Ͼ150 mg/dL (measured by enzymatic assay at the WISE core lipid laboratory), (3) HDL cholesterol (HDL-C) Ͻ50 mg/dL, (4) hypertension (systolic blood pressure Ն130 mm Hg, diastolic blood pressure Ն85 mm Hg, or use of antihypertensive drug therapy), and (5) fasting glucose Ն110 mg/dL. Women were classified into 3 mutually exclusive groups consisting of those with a history of treated diabetes (past use of oral hypoglycemic agents or insulin; nϭ192; 25%); those without treated diabetes who met the definition of the metabolic syndrome (nϭ259; 33%), and metabolic "normal" subjects (nϭ329; 42%). In some analyses, women with a history of diabetes or the metabolic syndrome were combined ("dysmetabolic") and compared with metabolic "normal" women.
Classification of Body Mass Index
Body mass index (BMI) was calculated as body weight in kilograms divided by the square of the height in meters (kg/m 2 ). Normal weight was defined as BMI Յ24.9 (nϭ184; 24%), overweight was defined as BMI Ն25.0 to Յ29.9 (nϭ269; 34%), and obesity was defined as BMI Ն30.0 (nϭ327; 42%). 24 We did not form a separate analysis group for "underweight" subjects (BMI Ͻ18.5), because only 13 subjects (1.7% of study cohort) met this definition, and the results were essentially unchanged when these subjects were excluded. We had the opportunity to use waist circumference as a measure of adiposity in lieu of or an as adjunct to BMI but chose to use BMI because it is not directly part of the definition of the metabolic syndrome.
Measurement of Inflammatory Markers
Plasma sampled at baseline was frozen at Ϫ70°C for subsequent measurement of inflammatory markers. IL-6 levels were measured from plasma collected at study entry with a commercially available ELISA kit (Quantikine hs human IL-6, R&D Systems). Levels of hs-CRP were measured by a high-sensitivity method on the Hitachi 911 analyzer with reagents from Denka Seiken and previously validated techniques. 25 
Assessment of Angiographic CAD
Quantitative analysis of coronary angiograms was performed offline at the WISE angiographic core laboratory (Rhode Island Hospital, Providence, RI) by investigators blinded to all other subject data. 26 Luminal diameter was measured at all stenoses and at nearby reference segments with an electronic cine projector-based crosshair technique (Vanguard Instrument Corporation). The presence of 1 or more stenoses Ն50% in diameter was considered significant CAD, maximum diameter stenosis 20% to 49% was considered minimal CAD, and Ͻ20% stenosis in all coronary arteries was considered no CAD.
Ascertainment of Cardiovascular Events
Follow-up for the occurrence of untoward cardiovascular events was obtained by annual telephone and/or mail contact. The primary clinical outcomes of interest were death or the composite end point of major adverse cardiovascular events (MACE; death, nonfatal myocardial infarction, stroke, or congestive heart failure). Among the 739 women who did not die during the 3-year follow-up, 87% had Ն1 year of follow-up, 81% had Ն2 years of follow-up, and 67% had Ն3 years of follow-up. The median length of follow-up was 3.5 years (interquartile range 2.8 to 4.7 years) among the 739 surviving women (94.7% of the total cohort), and 1.3 years for the 41 nonsurviving women (interquartile range 0.44 to 2.2 years).
Statistical Analysis
Differences in baseline demographic and clinical characteristics among the 3 BMI groups were assessed by 2 tests for categorical variables and Student t test or Wilcoxon rank sum tests for continuous variables. The latter nonparametric method was used due to relatively high skew of some baseline clinical variables, including lipids and inflammatory markers. Logistic regression analysis was used to obtain adjusted estimates of the odds of having significant angiographic CAD in relation to levels of BMI and metabolic status. The Kaplan-Meier method was used to estimate 3-year cumulative incidence rates of death and MACE, with the log-rank statistic used to assess differences by levels of BMI and metabolic status. Participants who did not experience the clinical outcome of interest were censored at either 3 years or the last date of follow-up before 3 years. Proportional hazards regression was used to estimate adjusted 3-year relative risks of death and MACE in relation to levels of BMI and metabolic status. Covariates in adjusted models included age and race, as well as those with a probability value of Ͻ0.10, as determined by forward stepwise regression. The proportional hazards assumption of invariant relative risk was tested and found to be satisfactory for all models constructed.
Results
Baseline Characteristics by BMI
Compared with normal and overweight women, obese women were significantly less likely to be white and to smoke cigarettes at study entry and significantly more likely to be taking antihypertensive medications and to have higher levels of triglycerides (Table 1 ). In addition, mean HDL cholesterol levels were lower in overweight (meanϭ53) and obese (meanϭ52) women than in women with normal BMI (meanϭ59, PϽ0.0001), whereas levels of the proinflammatory markers hs-CRP and IL-6 were significantly higher (PϽ0.0001) in overweight and obese women than in women with normal BMI. Metabolic status was strongly related to BMI, with 28% of women with normal BMI being dysmetabolic compared with 55% among overweight women and 76% among obese women (PϽ0.0001).
Angiographic CAD by Levels of BMI and Metabolic Status
A consistent pattern was seen between BMI and metabolic status in relation to the prevalence of significant angiographic CAD (Table 2 ). Among women with normal metabolic status, the prevalence of significant angiographic CAD was 29% in those with normal BMI, 25% in overweight women, and 17% in obese women. These rates were much lower than those documented in dysmetabolic women (56%, 52%, and 42%, respectively). These relations of metabolic status, but not BMI, being associated with prevalence of significant angiographic CAD persisted and remained statistically significant after adjustment for age, race, menopausal status, and physical activity. Specifically, compared with normal-weight women with normal metabolic status, dysmetabolic women who were normal weight, overweight, or obese had approximately 3.1, 2.6, and 1.9 times higher adjusted odds of having significant angiographic CAD.
Cardiovascular Events by Levels of BMI and Metabolic Status
A similar pattern of risk was observed when BMI was stratified by metabolic status and its association with cardiovascular events. Among women with normal metabolic status, 3-year survival rates were 95.8% in those with normal BMI, 97.8% in those who were overweight, and 98.7% in those who were obese (Figure 1 ). These survival rates were markedly higher than those observed in dysmetabolic women (normal BMI 86.6%, overweight 91.9%, obese 92.3%). Thus, the 3-year survival rate was significantly higher in women with normal metabolic status than in those who were dysmetabolic (97.2% versus 91.5%, Pϭ0.003), with consistently higher survival observed at all levels of BMI. Adjusted 3-year risks of death were also in the direction of higher risk being associated with a dysmetabolic status (Ϸ2-fold) but not BMI, yet this did not attain statistical significance, perhaps owing to low statistical power when the study cohort was stratified by levels of both BMI and metabolic status (Table 3) . Similar results were observed for 3-year event-free rates from MACE ( Figure 2 ; Table 3 ). Thus, dysmetabolic status, but not increasing levels of BMI, was associated with an increased risk of cardiovascular events. Moreover, within levels of metabolic status, obese and overweight individuals appeared to have nominally better 3-year event-free survival than those with normal BMI.
Inflammation by Levels of BMI and Metabolic Status
As a possible mechanism linking disturbed metabolic status, independent of body weight, with cardiovascular events, levels of inflammation (hs-CRP) were explored. At all levels of BMI, the prevalence of women with baseline hs-CRP values Ն1.5 mg/dL was highest among those who were dysmetabolic compared with those with normal metabolic status ( Figure 3) . This difference in inflammatory activity was particularly striking in overweight women, with only 4.9% of those with normal metabolic status having hs-CRP Ն1.5 mg/dL compared with 21.8% of women with disturbed 
Independent Effect of BMI Versus Metabolic Status on Cardiovascular Events
In both unadjusted and adjusted analyses (Table 4) , unit increases in BMI (from normal to overweight to obese) were not associated with 3-year risk of death (adjusted hazard ratio 0.92, 95% CI 0.59 to 1.51, Pϭ0.69) or MACE (adjusted hazard ratio 0.95, 95% CI 0.71 to 1.27, Pϭ0.73). In contrast, each unit increase in metabolic status (from normal to metabolic syndrome to diabetes) was associated with Ϸ2-fold adjusted risk of death (hazard ratio 2.01, 95% CI 1.26 to 3.20, Pϭ0.003) and MACE (hazard ratio 1.88, 95% CI 1.38 to 2.57, PϽ0.0001). Thus, the adverse effect of being dysmetabolic on long-term risk of cardiovascular events was independent of BMI, whereas being overweight or obese did not independently confer increased cardiovascular risk. These results were essentially unchanged when adjusting for baseline levels of hs-CRP (data not shown), thereby indicating that the adverse effect associated with dysmetabolic status was not principally due to (ie, confounded by) higher levels of inflammation in women who were dysmetabolic. Higher hs-CRP levels (log transformed) were suggestive of but not independently associated with 3-year risk of death (adjusted ‡For 3-year risk of death, HR was adjusted for age, race, prior myocardial infarction, chronic obstructive pulmonary disease, and number of lesions with Ն50% stenosis; 33 cases were excluded because of missing covariate data. For 3-year risk of MACE, HR was adjusted for age, race, prior myocardial infarction, chronic obstructive pulmonary disease, history of congestive heart failure, number of lesions with Ն50% stenosis, and physical activity level; 47 cases were excluded because of missing covariate data. 
Discussion
The prevalence of obesity, insulin resistance, and type 2 diabetes has increased steadily in the United States over the past 2 decades to the point of being viewed as epidemic. 1 In the present study of 780 women with suspected myocardial ischemia who were referred for coronary angiography, we observed a predictable but partially discordant relationship between increasing levels of BMI (normal versus overweight versus obese) and disturbed metabolic status (normal versus metabolic syndrome versus diabetes). Specifically, a minority (24%) of obese women did not have the metabolic syndrome or diabetes, whereas a parallel minority of women with normal BMI (28%) were classified as dysmetabolic (ie, with metabolic syndrome or diabetes). Abnormal metabolism was independently associated with a significantly increased risk of death or MACE. In contrast, increased BMI (ie, overweight and obesity) was not an independent predictor of cardiovascular risk.
Previous epidemiological studies have reported that obesity is an independent cardiovascular risk factor. [7] [8] [9] [10] However, the pathophysiological mechanism of this association is uncertain. The present data suggest that abnormal metabolism, manifested by the metabolic syndrome or diabetes, may explain in part this observation. This possibility is biologically plausible because central adiposity, which is a common manifestation of obesity, is associated with insulin resistance, which appears to be the underlying cause of the metabolic syndrome and type II diabetes. Furthermore, adipocytes produce proinflammatory cytokines, which might explain our and other observations of associations between abnormal metabolism and nonspecific inflammatory markers such as hs-CRP. 22 The present findings also indicate that normal-weight women with the metabolic syndrome have a significantly increased cardiovascular risk. Similarly, overweight and obese women with normal metabolism have a relatively low cardiovascular risk. These results suggest that the clinical evaluation of abnormal metabolism (ie, metabolic syndrome and diabetes) should play a more important role than the diagnosis of obesity per se in cardiovascular risk stratification in women. One possible explanation for this finding is that measurement of BMI to define overweight and obesity does not quantify the magnitude or ratio of subcutaneous to visceral fat in a given individual. The visceral fat area, which is associated with an insulin-resistant state, 27 appears to be an important link between many components of the metabolic syndrome, such as dyslipidemia and hypertension. 28 Furthermore, classification of weight status by measurements of waist and hip circumference, the ratio of which may provide a clinically useful estimation of the proportion of abdominal or upper-body fat, 29 also does not distinguish between accumulations of visceral and subcutaneous abdominal fat. Therefore, classification of weight status by routine measurements may underestimate the role of visceral fat distribution in the prediction of cardiovascular risk. This limitation of standard clinical measurements is germane to the present study because we do not know whether the present cohort of women with normal BMI and the metabolic syndrome had relatively high levels of visceral fat or, conversely, whether obese women with normal metabolic status had relatively low levels of visceral fat. Nevertheless, the present data suggest that classification of metabolic status by a simple and wellestablished clinical algorithm is more accurate than assessment of weight status alone for the stratification of cardiovascular risk in women.
The present study also demonstrated that inflammatory activity, as measured by levels of hs-CRP, was more closely associated with metabolic status than body weight. This finding is not fully intuitive, because adipose tissue is a source for the production and release of cytokines such as tumor necrosis factor-␣, IL-1␤, and IL-6, 30 which induce hepatic production of hs-CRP, 31 and because BMI has recently been shown to be a particularly strong correlate of hs-CRP. 32 However, cytokines may also directly impede insulin-stimulated glucose uptake, 33 which is consistent with the proposition that chronic subclinical inflammation should be considered a component of the definition of the metabolic syndrome. 19 Moreover, when evaluated above and beyond the effects of BMI and the metabolic syndrome, we found a trend toward an association between levels of hs-CRP and risk of cardiovascular events.
Study Limitations
Our study population of women with suspected myocardial ischemia who were referred for coronary angiography is highly selective; the present results may not be generalizable to women at large or to men. Furthermore, selection bias may have been present. Specifically, we found that (1) among women with normal metabolic status, only 17% of those classified as obese had significant angiographic CAD compared with 29% of those with normal BMI, and (2) the prevalence of smoking was lowest in obese women. Thus, we cannot rule out a possible differential survival effect whereby smoking and/or the presence of angiographic CAD is more lethal in obese women. Similarly, it is possible that the perception of chest pain differs by body weight such that overweight and obese women seek diagnosis and treatment at lower (earlier) levels of ischemia and obstructive CAD than women with normal BMI. Finally, statistical power was limited when simultaneously stratifying the study cohort by levels of BMI and metabolic status; this precluded our ability to demonstrate statistical significance for apparent clinically relevant risks (ie, 2-fold) of cardiovascular events.
Conclusions
In women with suspected myocardial ischemia, the presence of the metabolic syndrome is highly prognostic of future cardiovascular risk, whereas measurement of BMI alone appears to confer little independent value in cardiovascular risk stratification. Therefore, the evaluation of metabolic status with the NCEP ATP III guidelines 11 should be considered in all women, regardless of weight status. Although it remains prudent to recommend weight loss in overweight and obese women, control of all modifiable risk factors in both normal and overweight persons to prevent the transition to or reduce the manifestations of the metabolic syndrome should be considered the ultimate goal. Future studies of cardiovascular risk should not only incorporate the classification of metabolic status but should also evaluate the role of inflammatory activity as a potential mediator of the epidemiological association among obesity, metabolic status, and cardiovascular risk.
